Device Trial Radar · NCT05344521
A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells
Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
29
Planned (sponsor's estimate)
Start
Feb 2024
Primary completion
Feb 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Hamilton Health Sciences CorporationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AFP Innovation Fund; Ontario Institute for Regenerative Medicine; Stem Cell Network
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Burn injuries are one of the most severe skin injuries and lead to a complex wound healing response. When the skin is wounded, stem cells in the skin must respond fast to help repair the injured tissue. The damaged skin of burn patients contains cells that are still alive and have typical stem cell characteristics. Because stem cells are so important for wound healing, the investigators have combined them with an existing skin substitute, Integra®, to examine the potential wound healing benefits of these stem cells. This is an investigational treatment and a first in-human trial. The purpose of this study is to test the safety of using a patient's own stem cells combined with Integra®, which the investigators call Integra®-Stem Cells (Integra®-SC). The investigators hypothesize that Integra®-SC will result in improved wound healing, better scar quality, and decreased scar formation at one-year post-injury.
Conditions
- Burns
Interventions
Integra®Device
A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
Integra®-SCDevice
A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Number of participants with surgical site infectionsTime frame: Acute hospitalization (1-4 months post admission depending on severity of injury)
- Safety - Number of participants with non-healing woundsTime frame: Acute hospitalization (1-4 months post admission depending on severity of injury)
- Safety - Number of patients with poor scarring requiring additional (unplanned) operationTime frame: Discharge to to 1 year post-discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hamilton General Hospital
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.